2024
Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalInternational Myeloma Working GroupD-RVdEarly progressionData cutoffMedian followMedian time to progressionYear progression free survivalNewly diagnosed multiple myelomaHigh riskEstimate 3-year survivalPresence of del(17pR-ISS-3Time to progressionEffective induction regimenFirst-line therapyStem cell transplantationDepth of responseDocumented disease progressionCohort of patientsAge of diagnosisLong-term outcomesAlternative treatment approachesMedian OSImpact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.Peer-Reviewed Original ResearchNewly diagnosed myelomaD-RVdBlack patientsStatistically significant differenceInduction therapyR-ISSOverall survivalMedian ageInternational Myeloma Working Group Uniform Response CriteriaWhite patientsImproved depth of responsePresence of extramedullary diseaseNewly diagnosed multiple myelomaResponse rateMedian overall survivalR-ISS-3Effective induction regimenHigh-risk featuresStem cell transplantationDepth of responseSignificant differenceClinical trial findingsStandard of careHigh-risk classificationMedian PFS
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristics